Genomics Unveiled: India’s Path To Precision Medicine

New Delhi [India], February 21: In a densely populated nation like India, delivering personalized healthcare demands extraordinary commitment. Despite the rise of specialty hospitals, only 5% of the population has access to advanced diagnostic tests, according to Statista. This stark gap is what Yoda Diagnostics aims to bridge.

A Life-Saving Story of Genomics in Action

Prof. Mridula Sharma, a retired college principal, battled a life-threatening arrhythmia unresponsive to conventional treatments. After exhausting standard medications, her cardiologist recommended genomic testing. Yoda Diagnostics’ PGx—Cardiovascular panel sequencing revealed a mutation in the MYH7 gene, a known cause of hereditary heart disease. This insight led to targeted therapy, stabilizing her condition and significantly improving her quality of life.

Had Prof. Sharma lacked access to such diagnostics, her fate could have been different. While genomics is mainstream in countries like the US, Yoda Diagnostics was founded to bring this transformative power to India and democratize genomic healthcare.

The State of Genomics in India

Since the first human genome was sequenced in 2003, costs and time have plummeted. Today, sequencing can be completed in a day at a fraction of its original cost. Yet, precision medicine in India remains underutilized due to cost barriers, limited infrastructure, and regulatory constraints.

“Precision medicine is not a futuristic ideal; it’s a present-day necessity,” asserts Dr. Shaik Mohammed Naushad, Chief Scientific Officer at Yoda Diagnostics. The company offers a range of testing panels—from oncology to rare disease diagnostics—tailored for Indian patients. However, limited insurance coverage means the financial burden often falls on patients, making these life-saving advancements inaccessible for many.

Bridging the Gap: Yoda Diagnostics’ Commitment to Accessible Genomics

Despite the global genetic testing market surpassing $17 billion, India’s share remains modest at around $60 million. Yoda Diagnostics aims to change this by delivering precise, affordable, and globally benchmarked genetic testing solutions.

Establishing a state-of-the-art genomic lab in Hyderabad was no small feat. Founder Sudhakar Kancharla, inspired by American diagnostic models, sought to replicate their advanced framework in India, focusing on accessibility and affordability.

“For India, we need more than technology; we need accessibility and affordability,” says Kancharla, who previously established diagnostic labs and IT companies in the US. His vision extends beyond diagnostics—he advocates for genomic health as a standard component of patient care.

Leading the Charge: Innovation, Quality, and Patient Care

Yoda Diagnostics specializes in oncology panels, cardiovascular diagnostics, and rare disease panels. The company collaborates closely with clinicians to deliver precise, actionable results, adhering to global accreditation standards like NABL and ICMR. Their proprietary tools, designed per ACMG guidelines, provide germline and somatic genetic analysis with unmatched precision.

Founder’s Vision: A Personal Journey to Precision Medicine

Sudhakar Kancharla’s journey is both inspiring and personal. Born and raised in India, he pursued molecular biology in the US, working at top healthcare institutions. His expertise in molecular genetics and genomics in oncology and rare diseases motivated him to return to India to make precision medicine accessible.

“We saw the power of genomics in transforming patient care and wanted to bring it to the average Indian patient,” Kancharla shares. Yoda Diagnostics embodies this commitment through education initiatives, collaborations with hospitals, and awareness programs.

Building India’s Genomic Database: A Pioneering Initiative

For genomics to reach its full potential, building a comprehensive genetic database is crucial. Precision medicine relies on identifying genetic variations across populations, yet most global genomic databases are skewed toward Western populations, leaving India’s genetic diversity largely unexplored.

Yoda Diagnostics is addressing this gap by partnering with researchers to construct a robust Indian genomic database. This initiative aims to enhance patient care and advance research, particularly for conditions prevalent in South Asian communities.

The Road Ahead: Paving the Way for India’s Genomic Revolution

Mainstreaming precision medicine in India faces challenges—regulatory hurdles, data privacy concerns, and affordability. Yet, with the push for a national digital health ecosystem and genomic initiatives by Yoda Diagnostics, the future looks promising.

“Our vision is to make genomic testing as routine as an MRI or blood test,” Kancharla affirms. By merging international expertise with a commitment to Indian healthcare, Yoda Diagnostics is paving the way for a genomics-driven future. As awareness grows, India’s genomic revolution is not a distant dream—it’s on the horizon.

This is not just healthcare innovation; it’s a movement to empower every Indian with the knowledge and resources they need to take control of their health—one genome at a time.

If you have any objection to this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 24 hours.

chandan healthcare diagnostics franchise network Health healthcare business NABH NABL NSE Emerge pathology radiology

Chandan Healthcare Scales Franchise Network to 500+ Franchises; Targets 1,000 Franchises by FY27-End

Lucknow (Uttar Pradesh) [India], September 23: Chandan Healthcare Limited (NSE – CHANDAN), – an integrated diagnostics company offering pathology and radiology services, has expanded its diagnostic franchise network to 568 franchises within a short span of six months, strengthening its last-mile presence and diagnostic collection network. The Company plans to scale the network to 1,000 […]

Read More
AI healthcare breast cancer screening c-met cdsco clinical trials fda Health lord’s mark medical device thermal imaging

Lord’s Mark Industries Gets Nod for Final Clinical Trials of AI Breast Cancer Screening Device

New Delhi [India], September 23: Lord’s Mark Industries Limited has informed the BSE that its Technical Committee has approved the final clinical trial stage for its AI-powered, radiation-free wearable breast cancer screening device, with trials planned across the USA, Great Britain and Europe. The disclosure was made under Regulation 30 of the SEBI Listing Obligations […]

Read More
abbit dental disease cbct ct imaging gi stasis Health malocclusion pet care rabbit care rabbit health veterinary dentistry

When Rabbits Stop Eating: Looking Beyond the Teeth – The Emerging Role of Cone Beam CT in Rabbit Dental Disease

New Delhi [India], September 21: Rabbits have become increasingly popular companion animals over the last decade, thanks to their gentle temperament, intelligence and affectionate nature. Despite their growing popularity, rabbit health is often misunderstood, particularly when it comes to dental disease. Many owners assume that a rabbit refusing food is suffering from a digestive problem […]

Read More